Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Recurrent Squamous Cell Lung Carcinoma × rilotumumab × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Recurrent Squamous Cell Lung Carcinoma 1

Interventions

tremelimumab 1 talazoparib 1 rilotumumab 1 palbociclib 1 durvalumab 1 Nivolumab 1 Ipilimumab 1 Immunoglobulin G 1 Erlotinib Hydrochloride 1 Docetaxel 1 Disulfides 1 CTLA-4 Antigen 1 AZD4547 1 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡